Form 4: Singular Genomics Systems Executive Sam Ropp Reports Stock Transactions

Chief Commercial Officer Sam Ropp of Singular Genomics Systems, Inc. reports the vesting and disposal of restricted stock units (RSUs) and acquisition of common stock on March 15, 2024.

Summary

• On March 15, 2024, Sam Ropp, Chief Commercial Officer of Singular Genomics Systems, Inc., engaged in transactions involving the company's stock.
• Ropp disposed of 4,187 shares of common stock.
• These shares were acquired through the vesting of Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Singular Genomics Systems' common stock.
• The RSUs vest in 16 equal quarterly installments from March 15, 2023.
• Following these transactions, Ropp directly owns 50,250 derivative securities and 16,750 shares of common stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the trading activities of company executives. It is a standard practice for publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
• The transactions do not appear to have any impact on employees, customers, suppliers, or creditors.

Key Dates